People: Generex Biotechnology Corp (GNBT.O)

GNBT.O on Consolidated Issue listed on NASDAQ Capital Market

0.59USD
3:59pm EST
Price Change (% chg)

$-0.01 (-1.18%)
Prev Close
$0.60
Open
$0.61
Day's High
$0.61
Day's Low
$0.58
Volume
981,601
Avg. Vol
2,122,972
52-wk High
$1.14
52-wk Low
$0.08

view people for:

Summary

Name Age Since Current Position
Gluskin, Anna 58 2002 Chairperson of the Board, President, Chief Executive Officer
Perri, Rose 42 2005 Chief Financial Officer, Chief Operating Officer, Treasurer, Secretary, Director
Fletcher, Mark 43 2003 Executive Vice President, General Counsel
Bernstein, Gerald 76 2008 Vice President - Medical Affairs
Barratt, John 65 2003 Independent Director
McGee, Brian 48 2004 Independent Director
Masterson, Nola 62 2007 Independent Director
» Insider Trading

Biographies

Name Description
Gluskin, Anna Ms. Anna Gluskin is Chairperson of the Board, President, Chief Executive Officer of Generex Biotechnology Corp. She is Director since September 1997. Ms. Gluskin has served as the President and Chief Executive Officer of Generex since October 1997 and the Chairperson of the Generex Board of Directors since November 2002. She held comparable positions with Generex Pharmaceuticals Inc. from its formation in 1995 until its acquisition by Generex in October 1997. Ms. Gluskin is one of the founders of Generex.
Perri, Rose Ms. Rose Perri is Chief Operating Officer, Chief Financial Officer, Treasurer, Secretary and Director of Generex Biotechnology Corp. She is Director since September 1997. Ms. Perri has served as Treasurer and Secretary of Generex since October 1997 and as Chief Operating Officer since August 1998. She served as Acting Chief Financial Officer from November 2002 until April 2005 when she was appointed Chief Financial Officer. She was an officer of Generex Pharmaceuticals Inc. from its formation in 1995 until its acquisition by Generex in October 1997. Along with Ms. Gluskin, Ms. Perri is one of the founders of Generex.
Fletcher, Mark Mr. Mark Fletcher has served as Executive Vice President and General Counsel of Generex Biotechnology Corporation since April 2003. From October 2001 to March 2003, Mr. Fletcher was engaged in the private practice of law as a partner at Goodman and Carr LLP, a major Toronto law firm. From March 1993 to September 2001, Mr. Fletcher was a partner at Brans, Lehun, Baldwin LLP, a law firm in Toronto. Mr. Fletcher received his LL.B. from the University of Western Ontario in 1989 and was admitted to the Ontario Bar in 1991.
Bernstein, Gerald Gerald Bernstein, M.D. has served as Vice President Medical Affairs of Generex Biotechnology Corporation since October 2001. He served as a Director of Generex from October 2002 to May 2008. Dr. Bernstein acts as a key liaison for Generex on medical and scientific affairs to the medical, scientific and financial communities and consults with Generex under a consulting agreement on research and medical affairs and on development activities. Dr. Bernstein is an associate clinical professor at the Albert Einstein College of Medicine in New York and an attending physician at Beth Israel Medical Center, Lenox Hill Hospital and Montefore Medical Center, all in New York. He was president of the American Diabetes Association from 1998 to 1999.
Barratt, John Mr. John Barratt is an Independent Director of Generex Biotechnology Corporation since March 2003. Mr. Barratt is currently the Chairman of the Generex Compensation Committee and a member of the Generex Audit Committee and Corporate Governance and Nominating Committee. Mr. Barratt served as the Board Liaison Officer of The Caldwell Partners International from July 2006 until May 2009. From April 2005 to July 2006, Mr. Barratt served as Chief Operating Officer of The Caldwell Partners International. The Caldwell Partners International is a Canadian-based human capital professional services company. Mr. Barratt from January 2002 until February 2007 served as the court-appointed Responsible Person and Liquidation Manager of Beyond.com Corporation, Debtor-in-Possession, a U.S. Chapter 11 Bankruptcy case, in which capacity Mr. Barratt reported to the bankruptcy court and to the U.S. Trustee’s Office. From September 2000 to January 2002, Mr. Barratt acted in the capacity of Chief Operating Officer of Beyond.com Corporation, an electronic fulfillment provider. Mr. Barratt also serves as Chairman of the Independent Review Committees of BAM Split Corp. and Brookfield Investment Funds Management Inc. In addition, Mr. Barratt is a member of the Advisory Board and also served as interim Chief Financial Officer of Crystal Fountains Inc from September 2008 to May 2009.
McGee, Brian Mr. Brian McGee is an Independent Director of Generex Biotechnology Corporation since March 2004. Mr. McGee is currently the Chairman of the Generex Audit Committee and a member of the Generex Compensation Committee and Corporate Governance and Nominating Committee. Mr. McGee has been a partner of Zeifmans LLP ("Zeifmans") since 1995. Mr. McGee began working at Zeifmans shortly after receiving a B.A. degree in Commerce from the University of Toronto in 1985. Zeifmans is a Chartered Accounting firm based in Toronto, Ontario. A significant element of Zeifmans’ business is public corporation accounting and auditing. Mr. McGee is a Chartered Accountant. Throughout his career, Mr. McGee has focused on, among other areas, public corporation accounting and auditing. In 1992, Mr. McGee completed courses focused on International Taxation and Corporation Reorganizations at the Canadian Institute of Chartered Accountants and in 2003, Mr. McGee completed corporate governance courses on compensation and audit committees at Harvard Business School. In April 2004 Mr. McGee received his CPA designation from The American Institute of Certified Public Accountants.
Masterson, Nola Ms. Nola Masterson is an Independent Director of Generex Biotechnology Corporation since May 2007. Ms. Masterson is currently a Chairperson of the Generex Corporate Governance and Nominating Committee and a member of the Generex Audit Committee and Compensation Committee. Since 1982, she has been the chief executive officer of Science Futures Inc., an investment and advisory firm. Ms. Masterson is currently Managing Member and General Partner of Science Futures LLC, I, II and III, which are venture capital funds invested in life science funds and companies. She also serves as a Senior Advisor to TVM Techno Venture Management, an international venture capital company, and as a member of the Board of Directors of Repros Therapeutics Inc., a development stage biopharmaceutical company formerly known as Zonagen, Inc. (currently trading on The NASDAQ Global Market under the symbol “RPRX”). Ms. Masterson was the first biotechnology analyst on Wall Street, working with Drexel Burnham Lambert and Merrill Lynch, and is a co-founder of Sequenom, Inc., a genetic analysis company located in San Diego and Hamburg, Germany. She also started the BioTech Meeting in Laguna Nigel, CA, the annual Biopharmaceutical Conference in Europe, and was nominated to the 100 Irish American Business List in 2003. Ms. Masterson began her career at Ames Company, a division of Bayer, and spent eight years at Millipore Corporation in sales and sales management. Ms. Masterson has 31 years of experience in the life science industry. She received her Masters in Biological Sciences from George Washington University, and continued Ph.D. work at the University of Florida.

Basic Compensation

Name Fiscal Year Total
Gluskin, Anna 595,960
Perri, Rose 501,605
Fletcher, Mark 333,875
Bernstein, Gerald 229,500
Barratt, John --
McGee, Brian --
Masterson, Nola --
As Of 30 Jul 2009

Options Compensation

Name Options Value
Gluskin, Anna 1,970,704 1,847,610
Perri, Rose 1,376,752 1,053,980
Fletcher, Mark 1,221,726 1,041,790
Bernstein, Gerald 205,159 108,000
Barratt, John 0 0
McGee, Brian 0 0
Masterson, Nola 0 0

Insider Trading

Name Shares Traded Price
FLETCHER MARK 8,700 $0.52
GLUSKIN ANNA E 10,000 $0.51
PERRI ROSE C 10,000 $0.51
FLETCHER MARK 10,000 $0.49
MASTERSON NOLA E 50,000 $0.50
MASTERSON NOLA E 2,700 $0.69
FLETCHER MARK 2,200 $0.33
FLETCHER MARK 10,159 $0.32
FLETCHER MARK 24,500 $0.38
FLETCHER MARK 500 $0.37
PERRI ROSE C 3,800 $0.31
PERRI ROSE C 11,200 $0.30
FLETCHER MARK 250,000 $0.89
FLETCHER MARK 128,342 $1.16
FLETCHER MARK 100,000 $1.14
BERNSTEIN GERALD 50,000 $1.00
MASTERSON NOLA E 2,700 $1.06
BARRATT JOHN P 70,000 $1.00
» Full list on Insider Trading
view people for: